A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502672-23-00

Acronym

PRT2527-02

Enrollment

109

Registered

2023-09-14

Start date

2023-10-18

Completion date

2026-01-21

Last updated

2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia (AML), Aggressive B-Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic myelomonocytic leukemia (CMML), Mantle Cell Lymphoma (MCL), Marginal zone lymphoma (MZL), MDS/myeloproliferative neoplasm (MPN) overlap syndrome, Myelodysplastic syndrome (MDS), Richter's Syndrome, Small Lymphocytic Lymphoma (SLL), T-cell lymphoma (TCL) subtypes

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Germany, Italy, Poland

Outcome results